High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy (Q34605114)

3 August 2017

High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy (English)

1 reference

3 August 2017

8

Ulf Müller-Ladner

1 reference

3 August 2017

Eckhard Schulze-Lohoff

12

object named as

Eckhard Schulze-Lohoff

0 references

Gabriela Riemekasten

11

object named as

Gabriela Riemekasten

1 reference

3 August 2017

10

Christiane Pfeiffer

1 reference

3 August 2017

2

Pia Moinzadeh

1 reference

3 August 2017

13

Cord Sunderkoetter

1 reference

3 August 2017

3

Ekkehard Genth

1 reference

3 August 2017

6

Inga Melchers

1 reference

3 August 2017

1

Nicolas Hunzelmann

1 reference

3 August 2017

Thomas Krieg

4

1 reference

3 August 2017

Walter Lehmacher

5

1 reference

3 August 2017

Michael Meurer

7

1 reference

3 August 2017

Thorsten M Olski

9

1 reference

3 August 2017

Eckhard Schulze-Lohoff

12

1 reference

3 August 2017

Manfred Weber

14

1 reference

3 August 2017

German Network for Systemic Scleroderma Centers

15

1 reference

3 August 2017

4 March 2009

1 reference

Arthritis Research and Therapy

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

2

1 reference

3 August 2017

R30

1 reference

https://scigraph.springernature.com/pub.10.1186/ar2634

3 August 2017

0 references

cites work

The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Cyclophosphamide versus placebo in scleroderma lung disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Scleroderma--clinical and pathological advances

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Scleroderma overlap syndromes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Long-term outcomes of scleroderma renal crisis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Undifferentiated connective tissue syndromes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FAR2634

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FAR2634

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688174

Unclassified or undifferentiated connective tissue disease

26 October 2018

1 reference

12 December 2020

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

Scleroderma overlap syndromes

1 reference

12 December 2020

Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Progressive Systemic Sclerosis Sine Scleroderma

1 reference

12 December 2020

Scleroderma treatment differs between experts and general rheumatologists

1 reference

12 December 2020

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR2634

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference